![Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial]()
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trialLacosta, Ana-María; Pascual-Lucas, María; Pesini, Pedro; Casabona, Diego; Pérez-Grijalba, Virginia; Marcos-Campos, Iván; Sarasa, Leticia; Canudas, Jesus; Badi, Hassnae; Monleón, Inmaculada; San-José, Itziar; Munuera, Josep; Rodríguez-Gómez, Octavio; Abdelnour, Carla; Lafuente, Asunción; Buendía, Mar; Boada, Mercè; Tárraga, Lluis; Ruiz, Agustín; Sarasa, Manuel · Alzheimer's Research & Therapy · 2018